期刊文献+

LncRNA SNHG14调控miR-656-3p/SIRT5通路加重肝癌侵袭和迁移

LncRNA SNHG14 Regulates miR-6-3p/SIRT5 Pathway to Aggravate Liver Cancer Invasion and Migration
下载PDF
导出
摘要 目的:探讨长链非编码RNA(lncRNA)小核仁RNA宿主基因14(SNHG14)对肝细胞癌(HCC)细胞侵袭和迁移的影响及机制。方法:采用实时荧光定量聚合酶链式反应(qRT-PCR)检测肝癌细胞SNHG14和miR-656-3p的表达。与sh-SNHG14,miR-656-3p抑制剂,miR-656-3p模拟物,pcDNA3.1-SIRT5共转染后,检测HepG2和MHCC97H细胞增殖、侵袭和迁移。然后用qRT-PCR测定SNHG14、miR-656-3p和SIRT5的表达水平,荧光素酶报告基因检测和RNA下调SNHG14与miR-656-3p之间的关系,以及miR-656-3p与SIRT5之间的关系。结果:HCC细胞中SNHG14表达上调,miR-656-3p表达下调。抑制SNHG14和miR-656-3p过表达,可抑制HepG2和MHCC97H细胞增殖,侵袭和迁移。SNHG14直接作用于miR-656-3p,SIRT5是miR-656-3p的靶基因。miR-656-3p抑制剂或pcDNA3.1-SIRT5可逆转sh-SN HG14对肝癌细胞增殖、侵袭和迁移的抑制作用。结论:SNHG14通过调节miR-656-3p/SIRT5轴促进肝癌细胞的侵袭和迁移。 Objective To investigate the effect and mechanism of long non-coding RNA(lncRNA)small nucleolar RNA host gene 14(SNHG14)on the invasion and migration of hepatocellular carcinoma(HCC)cells.Methods Real-time fluorescent quantitative polymerase chain reaction(qRT-PCR)was used to detect the expression of SNHG14 and miR-656-3p in liver cancer cells.After co-transfection with sh–SNHG14,miR–656–3p inhibitor,miR–656–3p mimic,and pcDNA3.1–SIRT5,the proliferation,invasion and migration of HepG2 and MHCC97H cells were detected.Then qRT-PCR was used to determine the expression levels of SNHG14,miR-656-3p and SIRT5,luciferase reporter gene detection and RNA down-regulation between SNHG14 and miR-656-3p,and between miR-656-3p and SIRT5 Relationship.Results The expression of SNHG14 was up-regulated in HCC cells,and the expression of miR-656-3p was down-regulated.Inhibiting the overexpression of SNHG14 and miR-656-3p can inhibit the proliferation,invasion and migration of HepG2 and MHCC97H cells.SNHG14 acts directly on miR-656-3p,and SIRT5 is the target gene of miR-656-3p.miR–656–3p inhibitor or pcDNA3.1–SIRT5 can reverse the inhibitory effects of sh–SN HG14 on the proliferation,invasion and migration of liver cancer cells.Conclusion SNHG14 promotes the invasion and migration of liver cancer cells by regulating the miR–656–3p/SIRT5 axis.
作者 杨景波 李世通 孙大勇 江丹 YANG Jing-bo;LI Shi-tong;SUN Da-yong;JIANG Dan(The First Affiliated Hospital of Shenzhen University,The Second People's Hospital of Shenzhen,Guangdong Shenzhen 518035)
出处 《深圳中西医结合杂志》 2021年第12期5-8,199,200,共6页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词 肝细胞癌 小核仁RNA宿主基因14 miR-656-3p/SIRT5轴 Hepatocellular carcinoma Small nucleolar RNA host gene 14 miR-656-3p/SIRT5 axis
  • 相关文献

参考文献1

二级参考文献113

  • 1Steel JL, Nadeau K, Olek M, Carr BI. Preliminary results of anindividually tailored psychosocial intervention for patients withadvanced hepatobiliary carcinoma. J Psychosoc Oncol 2007; 25:19-42 [PMID: 19341012 DOI: 10.1300/J077v25n03_02].
  • 2Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis:from genes to environment. Nat Rev Cancer 2006; 6: 674-687[PMID: 16929323 DOI: 10.1038/nrc1934].
  • 3Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebasedmanagement of hepatocellular carcinoma--an updatedanalysis of randomized controlled trials. Aliment PharmacolTher 2006; 23: 1535-1547 [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x].
  • 4Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A,Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L.Liver transplantation for the treatment of small hepatocellularcarcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104].
  • 5Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A,Ascher NL, Roberts JP. Liver transplantation for hepatocellularcarcinoma: expansion of the tumor size limits does not adverselyimpact survival. Hepatology 2001; 33: 1394-1403 [PMID:11391528 DOI: 10.1053/jhep.2001.24563].
  • 6Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW,Lee SK. HCC in living donor liver transplantation: can we expandthe Milan criteria- Dig Dis 2007; 25: 313-319 [PMID: 17960066DOI: 10.1159/000106911].
  • 7Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K,Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansionof selection criteria for patients with hepatocellular carcinomain living donor liver transplantation. Liver Transpl 2007; 13:1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281].
  • 8Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, AishimaS, Terashi T, Shimada M, Maehara Y. Extended indication forliving donor liver transplantation in patients with hepatocellularcarcinoma. Transplantation 2007; 83: 893-899 [PMID: 17460559DOI: 10.1097/01.tp.0000259015.46798.ec].
  • 9Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, AscherNL, Roberts JP. Liver transplantation for hepatocellular carcinoma:analysis of survival according to the intention-to-treat principleand dropout from the waiting list. Liver Transpl 2002; 8: 873-883[PMID: 12360427 DOI: 10.1053/jlts.2002.34923].
  • 10Roayaie K, Feng S. Allocation policy for hepatocellular carcinomain the MELD era: room for improvement- Liver Transpl 2007; 13:S36-S43 [PMID: 17969067 DOI: 10.1002/lt.21329].

共引文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部